iBio, Inc.
Financial highlights
| Metric | FY June 30, 2025 | FY June 30, 2024 | FY June 30, 2023 | FY June 30, 2022 | FY June 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $400,000 | $225,000 | $0 | $1.9M | $2.4M |
| Gross profit | — | — | — | $2.2M | $909,000 |
| Operating income | -$18.6M | -$16.6M | -$29.3M | -$29.7M | -$31.1M |
| Operating expenses | $19.0M | $16.9M | $29.3M | $31.6M | $32.0M |
| Cost of revenue | — | — | — | $216,000 | $1.5M |
| Cash from operations | -$15.3M | -$18.6M | -$30.4M | -$37.5M | -$30.1M |
| Capital expenditure | $16,000 | $210,000 | $5.7M | $7.3M | $4.9M |
| Free cash flow | -$15.3M | -$18.8M | -$36.2M | -$44.8M | -$35.0M |
| Impairments | — | $3.1M | $17.9M | — | — |
| Total assets | $23.2M | $28.7M | $41.2M | $99.4M | $147.0M |
| Total liabilities | $8.3M | $7.4M | $25.8M | $35.9M | $38.4M |
Shares outstanding 49.7M · Free float 42.3%
Annual filing data through FY ended June 30, 2025; float as of July 13, 2026.